Biopure Corp. (BPUR) Receives Comment Letter From the U.K.
This morning, Biopure Corporation (Nasdaq: BPUR) announced that it has received a comment letter from the United Kingdom's Commission on Human Medicines addressing the company's application for marketing authorization for Hemopure [(R) hemoglobin glutamer - 250 (bovine)] pending with the Medicines and Healthcare products Regulatory Agency (MHRA). The commission was reassured on a number of questions raised in the initial comment letter. The comment letter invites Biopure to discuss the issues with the MHRA team. Biopure has not been advised to withdraw its application. "We intend to proceed by meeting and consulting with the UK regulatory review team, as suggested,…